Elevation of plasma TGF-b in cancer patients and study on its molecular mechanism.

我们已经报道，转化生长因子-β1是由人肝细胞癌和结肠癌产生的，在这些癌症患者中，血浆转化生长因子-β1浓度升高。循环中的转化生长因子-β1参与了抗肿瘤免疫功能的降低和血管的增加，我们的假设是循环中的转化生长因子-β1可能有助于患者的预后。我们将70例肝细胞癌患者分为高浓度组(>8.7 ng/ml)和低浓度组(<8.7 ng/ml)。高分流组存活时间较短。这一结果在每个肿瘤分期中都得到了证实。COX比例风险回归分析显示血浆中转化生长因子-β1浓度是影响预后的危险因素。同时，我们还在研究重组可溶性转化生长因子-β受体II对裸鼠人肝癌移植瘤的抗肿瘤作用。这些实验可能会导致对人类癌症患者进行抗转化生长因子-b治疗。

We have reported that TGF-bl is produced by human hepatocellular carcinoma and colon cancer and that plasma TGF-bl concentration is elevated in patients with these cancers. The circulated TGF-b1 contributed to reduced anti-tumor immunity and enhanced vascularity in the timors.Our hypothesis is that the circulating TGF-bl may contribute to prognosis of the patients. We divided 70 patients with hepatocellular carcinoma into a group with high concentration of plasma TGF-IA (more than 8.7 ng/ml) and a group with low concentration (below 8.7). The survival time was short in the group with high concenteration. This result was confirmed in each tumor stage. Cox proportional-hazard regression analysis showed that plasma TGF-bl concentration is a risk factor contributing for the prognosis.We also are studying on anti-tumor effect of recombinant soluble form TGF-b receptor type II against human hepatoma transplanted in nude mice. These experiments may lead to anti-TGF-b therapy in human cancer patients.